CERC vs. KNSA, PCRX, SYRE, LGND, VRNA, IRWD, PIRS, DCPH, COLL, and GMTX
Should you be buying Cerecor stock or one of its competitors? The main competitors of Cerecor include Kiniksa Pharmaceuticals (KNSA), Pacira BioSciences (PCRX), Spyre Therapeutics (SYRE), Ligand Pharmaceuticals (LGND), Verona Pharma (VRNA), Ironwood Pharmaceuticals (IRWD), Pieris Pharmaceuticals (PIRS), Deciphera Pharmaceuticals (DCPH), Collegium Pharmaceutical (COLL), and Gemini Therapeutics (GMTX). These companies are all part of the "medical" sector.
Cerecor (NASDAQ:CERC) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and community ranking.
Kiniksa Pharmaceuticals has a net margin of 2.78% compared to Cerecor's net margin of -1,194.82%. Kiniksa Pharmaceuticals' return on equity of -7.32% beat Cerecor's return on equity.
Kiniksa Pharmaceuticals has higher revenue and earnings than Cerecor. Cerecor is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
62.8% of Cerecor shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals shares are held by institutional investors. 45.7% of Cerecor shares are held by company insiders. Comparatively, 54.2% of Kiniksa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Cerecor has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500.
In the previous week, Kiniksa Pharmaceuticals had 26 more articles in the media than Cerecor. MarketBeat recorded 26 mentions for Kiniksa Pharmaceuticals and 0 mentions for Cerecor. Kiniksa Pharmaceuticals' average media sentiment score of 0.32 beat Cerecor's score of 0.16 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the news media.
Kiniksa Pharmaceuticals has a consensus price target of $30.00, indicating a potential upside of 70.36%. Given Kiniksa Pharmaceuticals' higher possible upside, analysts plainly believe Kiniksa Pharmaceuticals is more favorable than Cerecor.
Cerecor received 21 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 74.00% of users gave Cerecor an outperform vote while only 64.06% of users gave Kiniksa Pharmaceuticals an outperform vote.
Summary
Kiniksa Pharmaceuticals beats Cerecor on 12 of the 17 factors compared between the two stocks.
Get Cerecor News Delivered to You Automatically
Sign up to receive the latest news and ratings for CERC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CERC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
